How much calcium AKG do studies and labels give?
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| ABLE registry entry (NCT05706389)1 | 1 g a day of Ca-AKG versus placebo, in 500 mg pills | 120 middle-aged adults, planned | 6 months, plus 3 months follow-up |
| AEGIS registry entry (NCT07031128)2 | AKG tablets, 1 g once a day, oral, versus placebo tablets | 250 patients having coronary artery bypass grafting surgery, planned | Not stated |
| Hypertension registry entry (NCT06445244)5 | 500 mg, qd, of alpha-ketoglutarate (supplied as a 1000 mg capsule), plus lifestyle modification, versus lifestyle modification only | 30 patients with hypertension, planned | one month |
| Shenzhen Hygieia registry entry (NCT07114536)3 | Calcium AKG 0.5 g tablets, two taken twice daily (2 g a day), versus starch placebo tablets | 34 adults aged 45 to 75 | 12 weeks |
| Stanford registry entry (NCT07269704)4 | Calcium AKG 2 g/day, taken orally twice daily, single arm with no placebo | 17 participants having a second cataract surgery | 7 days before that surgery |
| Demidenko et al. (2021), retrospective study of Rejuvant6 | Fixed dose of two tablets per day; each dose contained 1 gram of calcium AKG with vitamin A (men) or vitamin D (women), timed-release; no comparator | 42 self-reported healthy people (14 women, 28 men) | 4 to 10 months |
Trial registry entries list 1 g a day of calcium AKG (ABLE, 120 adults planned) or AKG (AEGIS, 250 patients planned), 2 g a day of calcium AKG (Shenzhen, 34 adults; Stanford, 17 participants) and 500 mg, qd, of AKG (a hypertension entry, 30 patients planned), all by mouth, and a DailyMed search found no label for calcium AKG.12345
Doses and schedules in the studies
The table is set at the top of the page
Five of the entries above are registry records of planned or ongoing studies, many without results, and give each study's stated protocol. The trial supplies were 500 mg calcium AKG pills (ABLE), 0.5 g calcium AKG tablets (Shenzhen) and a 1000 mg alpha-ketoglutarate capsule (hypertension entry, which gives 500 mg, qd).135 Retail strengths are not sourced.
None of the studies states an on/off cycle for calcium AKG. The Demidenko authors say there remains very little data on longer term use of Rejuvant or higher doses of the product.6
Label status and what is not known
A DailyMed search found no label for calcium alpha-ketoglutarate, only three sprays listing ornithine alpha-ketoglutarate. A review of AKG research says the lack of human clinical evidence prompts research on ideal dosage and long-term safety.7
Arginine and ornithine forms
In study 2 of Campbell et al. (2006), 35 resistance-trained adult men (30-50 y old) were randomly assigned to ingest 4 g of L-arginine alpha-ketoglutarate (three times a day, i.e., 12 g daily, n = 20) or placebo (n = 15), with resistance training for 8 weeks.8 In a 1998 trial by De Bandt and colleagues of 54 burn patients, ornithine alpha-ketoglutarate was given enterally at 10, 20 or 30 g a day, as a bolus or a continuous infusion, in addition to the enteral diet, against a continuous infusion of an isonitrogenous soy protein mixture.9
Mixing, storage and syringe marks
The texts read give no water type or volume for mixing calcium AKG powder. They give no storage conditions before or after mixing either. A U-100 syringe does not apply to an oral tablet, capsule or powder, and no concentration is given; units and dosing covers syringe marks.
Frequently asked questions
What dose of calcium AKG do Milligram users log?
Milligram has no logged calcium AKG dose to report.
What side effects are stated for alpha-ketoglutarate in humans?
In a 1998 crossover trial by Bro and colleagues of calcium ketoglutarate granulate versus calcium carbonate tablets in 19 patients on chronic hemodialysis, five of 17 patients (29%) were withdrawn from calcium ketoglutarate within 1 to 2 weeks for intolerance (anorexia, vomiting, diarrhea, general uneasiness), and all five had pre-existing gastrointestinal symptoms.10
References
- ClinicalTrials.gov. NCT05706389: Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults?. 2027. clinicaltrials.gov
- ClinicalTrials.gov. NCT07031128: Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS). 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT07114536: Evaluation of the Efficacy of Calcium a -Ketoglutarate(AKG-Ca) in Improving Human Aging. 2025. clinicaltrials.gov
- ClinicalTrials.gov. NCT07269704: Effect of Nutritional Supplement Alpha-ketoglutarate for Age-related Ocular Disease. 2025. clinicaltrials.gov
- ClinicalTrials.gov. NCT06445244: α-ketoglutarate in Patients With Hypertension. 2024. clinicaltrials.gov
- Aging (journal). Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. 2021. pmc.ncbi.nlm.nih.gov
- Biomedicines (journal). Alpha-Ketoglutarate: A Metabolic Regulator of Cellular Homeostasis and Pathophysiology. 2026. pmc.ncbi.nlm.nih.gov
- PubMed. Pharmacokinetics, safety, and effects on exercise performance of L-arginine alpha-ketoglutarate in trained adult men. 2006. pubmed.ncbi.nlm.nih.gov
- PubMed. A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients. 1998. pubmed.ncbi.nlm.nih.gov
- PubMed. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. 1998. pubmed.ncbi.nlm.nih.gov